Search results
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Motley Fool via Yahoo Finance· 2 weeks agoVertex Pharmaceuticals (NASDAQ: VRTX) has long been known for its expertise in treating cystic...
FDA Accepts Vertex (VRTX), CRISPR's BLA Filings for Exa-Cel
Zacks via Yahoo Finance· 11 months agoVertex Pharmaceuticals VRTX and CRISPR Therapeutics CRSP announced that the FDA has accepted their...
Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 3 months agoVertex Pharmaceuticals Inc (NASDAQ:VRTX) maintains a robust market position with a focus on cystic...
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
Zacks via Yahoo Finance· 2 weeks agoVertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate,...
Vertex (VRTX) Gets Positive CHMP Opinion for Kaftrio Expanded Use
Zacks via Yahoo Finance· 8 months agoVertex's (VRTX) Kaftrio gets a positive opinion from the European Medicines Agency's Committee for...
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
Motley Fool via Yahoo Finance· 3 months agoSarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common:...
Why Vertex Stock Is Soaring Today
Motley Fool via Yahoo Finance· 5 months agoShares of Vertex Pharmaceuticals (NASDAQ: VRTX) are up by more than 11% headed into the latter half of Wednesday's trading session, catapulted higher by...
Insider Sell Alert: EVP and CMO Carmen Bozic Sells 5,650 Shares of Vertex Pharmaceuticals Inc (VRTX)
GuruFocus.com via Yahoo Finance· 6 months agoIn the realm of biotechnology and pharmaceuticals, insider trading activity is often scrutinized for...
Zacks Industry Outlook Highlights Tetra Tech, Energy Recovery and Vertex Energy
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – February 28, 2023 – Today, Zacks Equity Research discusses Tetra...
Vertex, CRISPR therapy for sickle cell passes FDA panel test
BioPharma Dive via Yahoo Finance· 6 months agoThe high-profile meeting focused on the theoretical risks of CRISPR gene editing, as both the FDA...